Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly?
So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...
C&EN17h
Cashing in on founder-led biotech
Scientists who want a say in the future of their inventions are once again moving from academia to the C-suite ...
Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...
The Globe and Mail17h
2 S&P 500 Dividend Stocks That Could Soar 30% or More, According to a Pair of Wall Street Analysts
From Oct. 11 through Nov. 6, shares of Eli Lilly fell 16.7%, largely in response to third-quarter results that missed Wall Street expectations. Management also lowered the midpoint of its 2024 earning ...
Yahoo23h
The Woman’s World Expert-Reviewed Glossary of GLP-1, Semaglutide and Telehealth
With the rising popularity of telehealth providers offering GLP-1 medications like Ozempic, the terminology can get confusing ...
Hosted on MSN15h
Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand?
GIPR is involved in insulin release and glycemic control. Rival drugs from Eli Lilly and Viking Therapeutics also target GIPR, but they mimic it. Renza noted the placebo group had a higher bone ...